MK-886

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

<templatestyles src="Chembox/styles.css"/>

Template:Chembox image cellTemplate:Chembox AllOtherNamesTemplate:Chembox headerbarTemplate:Chembox IndexlistTemplate:Chembox JmolTemplate:Chembox ChEMBLTemplate:Chembox ECHATemplate:Chembox E numberTemplate:Chembox IUPHAR ligandTemplate:Chembox UNIITemplate:Chembox CompToxTemplate:Chembox headerbarTemplate:Chembox HazardsTemplate:Chembox Datapage checkTemplate:Yesno
MK-886
Template:Longitem Template:Unbulleted list
ChEBI Template:Unbulleted list
ChemSpider Template:Unbulleted list
DrugBank Template:Unbulleted list
EC Number Template:Unbulleted list
KEGG Template:Unbulleted list
MeSH L+663536
Template:Longitem Template:Unbulleted list
RTECS number Template:Unbulleted list
Script error: No such module "collapsible list".
Script error: No such module "collapsible list".
Template:Longitem C27H34ClNO2S
Molar mass 472.083

Template:Chembox Footer/tracking container onlyScript error: No such module "TemplatePar".Template:Short description

MK-886, or L-663536, is a leukotriene antagonist. It may perform this by blocking the 5-lipoxygenase activating protein (FLAP), thus inhibiting 5-lipoxygenase (5-LOX),[1] and may help in treating atherosclerosis.[2]

MK-886 is a synthesized chemical compound known for its role in inhibiting the 5-lipoxygenase-activating protein (FLAP). Key part in leukotriene biosynthesis. It has potential therapeutic applications in different types of cancer when paired up with other synthetically made chemical compounds. This includes the cancer cells doing apoptosis and suppress tumor cell growth independent from leukotriene inhibition with some cases.

Mechanism of action

Originally MK-886 was made as a FLAP inhibitor which has some interference with the leukotriene pathway. This is done by blocking 5-lipoxygenase which is an enzyme which aids in the synthesis of pro-inflammatory leukotrienes which is linked to some inflammatory diseases and cancers.

Cancer research and apoptosis

Several studies have shown the anti-cancer potential of MK-886. In a 2004 study MK-886 was shown to induce apoptosis in gastric cancer cells through the upregulation of the pro-apoptotic proteins p27^kip1 and Bax. This shows that the compound may promote cell death through a pathway that is at least partially independent of its role in leukotriene inhibition.[3]

In another study from 2007 researchers investigated the combined inhibition of 5-lipoxygenase and cyclooxygenase-2 (COX-2) in premalignant and malignant lung cell lines. MK-886 when combined with a COX-2 inhibitor significantly enhanced growth arrest and cell death. This shows a synergistic effect when targeting multiple inflammatory pathways in cancer therapy.[4]

Therapeutic potential

Due to its ability to both function in inflammatory and apoptotic pathways MK-886 has gained some recognition as a therapeutic agent for not a solo case of inflammatory diseases but also for cancers where leukotriene signaling, specially, helps to promote the tumors survival and growth.

References

<templatestyles src="Reflist/styles.css" />

  1. Script error: No such module "Citation/CS1".
  2. Script error: No such module "Citation/CS1".
  3. Script error: No such module "Citation/CS1".
  4. Script error: No such module "Citation/CS1".

Script error: No such module "Check for unknown parameters".

Template:Leukotriene signaling modulators Template:PPAR modulators

Template:Asbox